JUSINDO, Vol. 6 No. 2, Juli 2024
p-ISSN: 2303-288X, e-ISSN: 2541-7207

Update on Hepatitis C Virus (HCV) Vaccine Candidates in Clinical Trials: A Systematic Literature Review

Suratno Lulut Ratnoglik[1*], Matahari Harumdini[2]
Department of Clinical Microbiology, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia[1]
Jakarta Islamic Hospital Cempaka Putih, Jakarta, Indonesia[2]
[*]Corresponding Author. Email: suratno.lulut01@ui.ac.id

Keywords:
Hepatitis C virus; vaccine candidates; vaccine platforms; clinical trials; immunogenicity; efficacy

ABSTRACT

Introduction: Hepatitis C virus (HCV) infection remains a significant global health challenge, affecting over 71 million people worldwide and leading to severe liver diseases such as cirrhosis and hepatocellular carcinoma (HCC). Despite the availability of highly effective direct-acting antiviral (DAA) therapies achieving sustained virologic response (SVR) rates exceeding 90%, high costs and limited accessibility impede global eradication efforts. Additionally, DAAs do not confer immunity against reinfection, highlighting the need for a prophylactic vaccine. **Methods:** This systematic literature review follows the PRISMA guidelines. A comprehensive search was conducted in PubMed, Scopus, and Web of Science for articles published between January 2010 and March 2024, focusing on HCV vaccine candidates in clinical trials. Data on study characteristics, participant demographics, vaccine characteristics, vaccine platforms and key outcomes were extracted. **Results:** Nine studies met the eligibility criteria, covering various phases of clinical trials (Phase I, II, and II/III). Key findings included: ***Vaccine platforms*:** The studies primarily utilized three types of vaccine platforms: Viral Vector-Based Vaccines, Peptide-Based Vaccines and Recombinant Protein Vaccines ***Immunogenicity*:** Vaccines targeting non-structural proteins (NS3, NS4, NS5) induced robust T-cell responses. Chimpanzee adenovirus (ChAd) and Modified Vaccinia Ankara (MVA) vector-based vaccines showed high polyfunctional CD8+ and CD4+ T-cell levels. ***Safety*:** Most adverse events were mild to moderate, including flu-like symptoms and injection site reactions. Severe adverse events were noted with TG4040 when combined with PEG-IFNα and RBV. ***Efficacy*:** Significant reductions in viral load and improvements in liver function were reported. Personalized peptide vaccines demonstrated enhanced immune responses and improved overall survival in HCV-positive advanced HCC patients. **Conclusion:** HCV vaccine development has made significant strides, with several candidates demonstrating strong immunogenicity, acceptable safety, and promising efficacy in clinical trials. Continued research is essential to address challenges such as viral genetic variability, durability of immune responses, and global accessibility.

Coresponden Author: Suratno Lulut Ratnoglik
Email: suratno.lulut01@ui.ac.id

Introduction

Hepatitis C virus (HCV) infection continues to pose a significant global health challenge, affecting over 71 million individuals worldwide and leading to severe liver diseases such as cirrhosis and hepatocellular carcinoma (HCC) according to World Health Organization report in 2017 (WHO, 2017). Despite the availability of highly effective direct-acting antiviral (DAA) therapies that can achieve sustained virologic response (SVR) rates exceeding 90%, the high cost and limited accessibility of these treatments, particularly in low- and middle-income countries, impede global eradication efforts (Chen & Morgan, 2006). Moreover, DAAs do not confer immunity against reinfection, underscoring the urgent need for a prophylactic vaccine.

The pathogenesis of HCV is complex, with the virus exhibiting a high degree of genetic variability, which poses a significant obstacle to vaccine development (Simmonds et al., 2005). HCV's ability to evade the host immune response further complicates the development of an effective vaccine (Tarr et al., 2015). Nonetheless, insights into the immune responses associated with spontaneous viral clearance in some individuals have guided vaccine research towards inducing similar protective immune responses.

T-cell mediated immunity is considered crucial for controlling HCV infection, as evidenced by the association of strong, multi-specific CD4+ and CD8+ T-cell responses with the resolution of acute HCV infection (Rehermann & Thimme, 2019). Vaccine candidates that elicit robust T-cell responses have shown promise in preclinical and early clinical trials. For instance, viral vector-based vaccines using platforms such as adenovirus and Modified Vaccinia Ankara (MVA) have demonstrated the ability to induce potent HCV-specific T-cell responses (Bailey et al., 2019).

Several promising HCV vaccine candidates have progressed to clinical trials, focusing on various immunogenic components of the virus. These include viral vectors encoding non-structural proteins (NS3, NS4, NS5), recombinant proteins, and peptide-based vaccines(Bailey et al., 2019). Among these, vaccines targeting non-structural proteins have garnered significant interest due to their ability to induce strong cellular immune responses (Walker, 2010). For example, a chimpanzee adenovirus vector encoding HCV NS3-NS5B proteins has shown promising immunogenicity and safety profiles in phase I trials (Barnes et al., 2012).

In addition to T-cell responses, the role of neutralizing antibodies in preventing HCV infection is also being explored. Although challenging to induce, broadly neutralizing antibodies could potentially provide sterilizing immunity (Drummer, 2014). Efforts are ongoing to identify and enhance the generation of these antibodies through vaccination strategies (De Jong et al., 2014).

Despite these advancements, the development of an HCV vaccine faces several challenges. The high genetic diversity of HCV, the need for a durable and broad immune response, and the complexity of inducing both cellular and humoral immunity are significant hurdles (Walker & Grakoui, 2015). Additionally, ensuring the safety and efficacy of vaccine candidates across diverse populations remains a critical goal for ongoing research (Chen & Morgan, 2006).

This systematic literature review aims to provide an updated overview of HCV vaccine candidates currently undergoing clinical trials. By synthesizing recent findings, this review highlights the progress made in HCV vaccine development and identifies areas where further research is needed. It focuses on the vaccine platform, the immunogenicity, safety, and efficacy

of various vaccine candidates, offering a comprehensive update on the current status of HCV vaccine research.

Research Methods

This systematic literature review follows the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines to provide an update on Hepatitis C Virus (HCV) vaccine candidates in clinical trials. The review process involved systematic searching, screening, data extraction, and analysis.

Search Strategy

We conducted a comprehensive literature search in three major databases: PubMed, Scopus, and Web of Science. The search was limited to articles published between January 2010 and March 2024 to ensure the inclusion of the most recent and relevant studies. The following search terms were used: "HCV vaccine," "Hepatitis C vaccine," "clinical trials," "immunogenicity," "safety," and "efficacy." Boolean operators (AND, OR) were employed to combine search terms effectively. Additionally, reference lists of identified articles were manually screened to capture any additional relevant studies.

Inclusion and Exclusion Criteria

Inclusion criteria:

1. Studies published in English.
2. Clinical trials evaluating HCV vaccine candidates.
3. Articles reporting on immunogenicity, safety, and/or efficacy of the HCV vaccines.
4. Studies including human participants.

Exclusion criteria:

1. Review articles, editorials, and commentaries.
2. Animal studies and preclinical trials.
3. Studies without full-text availability.
4. Articles not providing primary data on the outcomes of interest (immunogenicity, safety, efficacy).

Study Selection

All identified articles were imported into EndNote for reference management. Duplicate entries were removed. Two independent reviewers (Reviewer A and Reviewer B) screened the titles and abstracts of the remaining articles for relevance. Full-text articles were retrieved for further assessment if the abstracts met the inclusion criteria or if there was insufficient information in the abstracts to make a clear decision. Discrepancies between reviewers were resolved through intensive discussion with both reviewers.

Data Extraction

A standardized data extraction form was developed and pilot-tested by the reviewers. The following information was extracted from each included study:

1. Study characteristics (authors, publication year, country, study design, phase of the trial).
2. Participant characteristics (sample size, age, gender, health status).
3. Vaccine characteristics (type of vaccine, dosage, administration route).
4. Outcomes measured (immunogenicity, safety, efficacy).

5. Main findings (immune response data, adverse events, efficacy results).

Data extraction was performed independently by Reviewer A and Reviewer B. Any discrepancies were resolved through discussion or consultation with Reviewer C.

Quality Assessment

The quality of the included studies was assessed using the Cochrane Collaboration's tool for assessing risk of bias in randomized trials. The following domains were evaluated:

1. Random sequence generation.
2. Allocation concealment.
3. Blinding of participants and personnel.
4. Blinding of outcome assessment.
5. Incomplete outcome data.
6. Selective reporting.
7. Other sources of bias.

Each domain was rated as low risk, high risk, or unclear risk. The overall quality of each study was categorized as high, moderate, or low based on the ratings across all domains.

Ethics and Dissemination

Ethical approval was not required for this systematic review as it involved the analysis of published data. The findings of this review will be disseminated through peer-reviewed publications and presentations at scientific conferences.

Result and Discussion

Result

Study selection

Identification

A total of 2,436 records were identified through database searches, and 34 additional records were identified through manual searches. After removing 412 duplicates, 2,058 unique records remained.

Screening

Titles and abstracts of the remaining records were screened, resulting in the exclusion of 1,579 records that did not meet the inclusion criteria.

Eligibility

Full texts of 479 articles were assessed for eligibility, leading to the exclusion of 470 articles that did not provide substantial data on clinical outcomes or focused solely on therapeutic vaccines.

Included Studies

Nine studies met the eligibility criteria and were included in the qualitative synthesis. The PRISMA flow diagram (**Figure 1**) illustrates the study selection process.



Figure 1 The PRISMA flow diagram

Quality Assessment

The quality of the nine included studies was assessed using the Cochrane Collaboration's tool for assessing the risk of bias in randomized trials. Each study was evaluated across seven domains: random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data, selective reporting, and other sources of bias. The overall quality of each study was categorized as high, moderate, or low based on the ratings across all domains (Table 1).

Low Risk: Adequate measures were reported and implemented to minimize bias in this domain.

Unclear Risk: Insufficient information was provided to determine the risk of bias in this domain.

High Risk: Significant issues were identified that could introduce bias in this domain.

Table 1 Quality Assessment of the nine included studies

Study	Random Sequence Generation	Allocation Concealment	Blinding of Participants and Personnel	Blinding of Outcome Assessment	Incomplete Outcome Data	Selective Reporting	Other Sources of Bias	Overall Quality	References
Swadling et al., 2014	Low Risk	Low Risk	Unclear Risk	Unclear Risk	High Risk	Unclear Risk	Unclear Risk	Moderate	**(Swadling et al., 2014)**
Hartnell et al., 2019	Low Risk	Low Risk	Low Risk	Low Risk	Low Risk	Low Risk	Low Risk	High	**(Hartnell et al., 2019)**
Di Bisceglie et al., 2014	Low Risk	Low Risk	Low Risk	Low Risk	Low Risk	Low Risk	Low Risk	High	**(Di Bisceglie et al., 2014)**
Colombatto et al., 2014	Unclear Risk	Unclear Risk	Unclear Risk	Unclear Risk	High Risk	Unclear Risk	Unclear Risk	Low	**(Colombatto et al., 2014)**
Han et al., 2020	Low Risk	Low Risk	Low Risk	Low Risk	Low Risk	Low Risk	Low Risk	High	**(Han et al., 2020)**
Firbas et al., 2006	Low Risk	Low Risk	Low Risk	Low Risk	Low Risk	Low Risk	Low Risk	High	**(Firbas et al., 2006)**
Jacobson et al., 2023	Low Risk	Low Risk	Low Risk	Low Risk	Low Risk	Low Risk	Low Risk	High	**(Jacobson et al., 2023)**
Yutani et al., 2015	Unclear Risk	Unclear Risk	Unclear Risk	Low Risk	Low Risk	Unclear Risk	Low Risk	Moderate	**(Yutani et al., 2015)**
Page et al., 2021	Unclear Risk	Unclear Risk	Unclear Risk	Low Risk	Low Risk	Unclear Risk	Low Risk	Moderate	**(Page et al., 2021)**

This table summarizes the risk of bias assessment for each study included in the systematic review. The overall quality of the studies was categorized based on the cumulative assessment across all domains.

Study Characteristics

The nine included studies were conducted between 2010 and 2023, covering various phases of clinical trials (Phase I, II, and II/III). The studies were primarily conducted in high-resource settings with diverse participant populations, including healthy volunteers and individuals with chronic HCV infection. The sample sizes ranged from 42 to 200 participants.

The immunogenicity, safety, and efficacy outcomes for each HCV vaccine candidate were summarized in Table 2.

Table 2 The immunogenicity, safety, and efficacy outcomes for each HCV vaccine candidate

Study	Sample Size	Phase	Vaccine Platform	Targeted Proteins	Immunogenicity	Safety	Efficacy Outcomes
Swadling et al., 2014	15	I	Viral Vector-Based	NS3-5B	Strong T cell response	Well tolerated	Sustained T cell memory
Hartnell et al., 2019	40	I	Viral Vector-Based	NS3-NS5	Enhanced T cell response	Acceptable	Dual prevention against HIV-1 and HCV

Di Bisceglie et al., 2014	153	II	Recombinant Protein	Core	Improved CD8+ T cell response	Well tolerated	Significant reduction in viral load
Colombatto et al., 2014	39	II	Recombinant Protein	E1E2	Enhanced antibody response	Well tolerated	Improved response in combination therapy
Han et al., 2020	24	I	Peptide-Based	Core, NS3	Increased T cell responses	Well tolerated	Reduction in regulatory T cells
Firbas et al., 2006	128	I	Peptide-Based	Peptides	Dose-dependent immune response	Safe	Optimal dosing established
Jacobson et al., 2023	40	I	Viral Vector-Based	NS3/4A	Enhanced immune response	Well tolerated	Prevention of HCC in HCV patients
Yutani et al., 2015	26	II	Peptide-Based	Personalized	Enhanced immune response	Safe	Targeted therapy in HCC
Page et al., 2021	548	III	Recombinant Protein	NS3, NS4, NS5	Strong antibody and T-cell response	Safe	Prevention of chronic HCV infection

Discussion

The pursuit of an effective Hepatitis C Virus (HCV) vaccine has become increasingly imperative, given the virus's global burden and the limitations of current therapeutic approaches. Despite the success of direct-acting antivirals (DAAs) in achieving high cure rates, their high costs, limited accessibility, and inability to prevent reinfection necessitate the development of a prophylactic vaccine. This discussion synthesizes findings from nine clinical trials on HCV vaccine candidates, evaluating their immunogenicity, safety, and efficacy while addressing the progress made, challenges encountered, and future directions for research.

The quality assessment

The quality assessment of the included studies indicates a generally high standard of methodology, particularly in the more recent trials. Studies such as those by Hartnell et al. (2019), Di Bisceglie et al. (2014), Han et al. (2020), Firbas et al. (2006), and Jacobson et al. (2023) consistently demonstrated low risk of bias across multiple domains, including random sequence generation, allocation concealment, and blinding, leading to an overall high quality rating. However, some studies, such as those by Colombatto et al. (2014) and Yutani et al. (2015), had several unclear risk areas, particularly in blinding and allocation concealment, which lowered their overall quality ratings to moderate or low. The findings underscore the importance of rigorous methodological practices in enhancing the reliability and validity of clinical trial results, particularly in the context of vaccine development for HCV. The varying degrees of risk of bias observed highlight the need for ongoing improvements in trial design, particularly in areas of blinding and reporting to ensure robust and trustworthy outcomes.

Sample Size and Phase

The studies reviewed encompass a broad spectrum of sample sizes and clinical phases, reflecting the diverse stages of research and development in the quest for an effective HCV vaccine. Swadling et al. (2014) conducted a Phase I study involving 15

participants, focusing on initial safety and immunogenicity assessments. Early-phase studies like this are crucial for identifying potential issues before progressing to larger-scale trials, providing foundational data on the vaccine's biological activity and safety profile (Swadling et al., 2014). Similarly, Hartnell et al. (2019) conducted another Phase I trial with 40 participants, designed to assess safety and immune responses in a controlled environment, offering critical data for subsequent phases and helping refine the vaccine candidate for broader testing (Hartnell et al., 2019).

Transitioning to larger and more diverse populations, Di Bisceglie et al. (2014) conducted a Phase II study involving 153 patients to evaluate the vaccine's efficacy in combination with peg-interferon and ribavirin (Di Bisceglie et al., 2014). Mid-phase trials like this aim to refine dosing, further evaluate safety, and assess the vaccine's therapeutic potential in a more extensive cohort. Colombatto et al. (2014) also conducted a Phase II randomized controlled trial with 39 patients, testing the HCV E1E2-MF59 vaccine, which is essential for determining optimal dosing and further evaluating safety and efficacy before moving to larger Phase III trials (Colombatto et al., 2014).

Han et al. (2020) conducted a Phase I trial with 24 participants, investigating the IFNL3-adjuvanted HCV DNA vaccine, focusing on immunogenicity and safety.(Han et al., 2020) This trial's relatively small size allows for detailed monitoring and adjustment based on initial findings. Firbas et al. (2006) conducted a Phase I trial with 128 healthy subjects aimed at dose optimization for an HCV peptide vaccine. The relatively large sample size for a Phase I trial underscores the importance of determining the optimal dose that balances safety and immunogenicity.(Firbas et al., 2006)

Jacobson et al. (2023) conducted a Phase I study with 40 participants, focusing on a therapeutic DNA vaccine aimed at preventing hepatocellular carcinoma in patients with chronic HCV infection. Early-phase results are pivotal in shaping the direction of subsequent research phases. Yutani et al. (2015) conducted a Phase II study with 26 participants, exploring personalized peptide vaccination for treating HCV-positive advanced hepatocellular carcinoma, combining HCV-derived peptides with tumor-associated antigens. Personalized approaches are increasingly important in targeting specific patient needs.

Page et al. (2021) conducted a large Phase III trial with 548 participants, examining a vaccine regimen to prevent chronic HCV infection. Phase III trials are crucial for confirming efficacy in larger, more diverse populations and detecting less common side effects, ensuring the vaccine's safety and effectiveness before potential market approval.

Vaccine Platforms

The reviewed studies employed various vaccine platforms, each offering distinct advantages.

Viral Vector-Based Vaccines: These vaccines, such as Chimpanzee adenovirus (ChAd) and Modified Vaccinia Ankara (MVA) vectors, demonstrated strong T-cell responses and were generally well-tolerated. These viral vectors have shown high polyfunctional CD8+ and CD4+ T-cell levels, indicating robust immunogenicity essential for effective vaccination against HCV. For instance, Swadling et al. (2014) and Hartnell

et al. (2019) highlighted the capacity of these vectors to prime and sustain functional HCV-specific T cell memory, which is crucial for long-term protection.

Peptide-Based Vaccines: These personalized peptide vaccines, tailored to individual patients, have shown promise in enhancing immune responses and improving overall survival in HCV-positive advanced HCC patients. The ability to customize these vaccines based on individual antigen profiles allows for a targeted immune response, improving efficacy in treating HCV-related complications. Yutani et al. (2015) reported significant enhancements in immune responses with personalized peptide vaccination, demonstrating the potential of this platform in HCV vaccine development. **Recombinant**

Protein Vaccines: These vaccines target specific viral proteins, such as non-structural proteins (NS3, NS4, NS5), to induce robust T-cell responses. Recombinant protein vaccines have been effective in eliciting both cellular and humoral immune responses, essential for comprehensive viral control. Studies like those by Colombatto et al. (2014) and Page et al. (2021) showed that these vaccines could enhance antibody responses and prevent chronic HCV infection, respectively, underscoring their potential in HCV prevention.

Targeted Proteins

The targeted proteins in HCV vaccine development play a pivotal role in determining the vaccine's efficacy and the nature of the immune response elicited. Swadling et al. (2014) and Hartnell et al. (2019) targeted multiple non-structural proteins, including NS3, NS4, and NS5, which are critical for viral replication and are well-recognized by the immune system. These proteins make ideal targets for eliciting a robust cellular immune response, aiming to disrupt the virus's life cycle and enhance the body's ability to fight infection. Di Bisceglie et al. (2014) focused on the core protein, a highly conserved region of the virus essential for the viral life cycle and immune recognition, targeting conserved regions to ensure vaccine effectiveness across various HCV genotypes.

Colombatto et al. (2014) targeted the envelope glycoproteins E1 and E2, which are key to viral entry into host cells and highly immunogenic, capable of inducing neutralizing antibodies critical for preventing viral entry and subsequent infection. Han et al. (2020) investigated a vaccine targeting core and NS3 proteins, involved in viral replication and immune modulation, aiming to elicit a broad and effective immune response. Firbas et al. (2006) utilized synthetic peptides representing different regions of the HCV proteome, aiming to elicit a broad immune response and generate a multi-faceted immune response targeting various aspects of the virus.

Jacobson et al. (2023) and Yutani et al. (2015) focused on therapeutic vaccines targeting both viral antigens and tumor-associated antigens to prevent and treat HCV-related hepatocellular carcinoma. This dual-target strategy can enhance the immune system's ability to fight both the virus and associated cancer.

Immunogenicity

Immunogenicity, the ability of a vaccine to induce an immune response, is a critical measure of its potential effectiveness. Swadling et al. (2014) demonstrated sustained T

cell memory responses, crucial for long-term immunity, highlighting the importance of using adenoviral vectors to prime and boost the immune response effectively, suggesting that this approach could provide durable protection. Hartnell et al. (2019) observed enhanced T cell responses, particularly in the context of dual prevention for HIV-1 and HCV, indicating the potential for broad-spectrum immune protection essential for populations at risk of multiple infections.

Di Bisceglie et al. (2014) reported significant improvements in CD8+ T cell responses when TG4040 was combined with peg-interferon and ribavirin, underscoring the potential of combination therapies to enhance immunogenicity and therapeutic outcomes. Colombatto et al. (2014) observed increased antibody responses with the E1E2-MF59 vaccine, highlighting the role of adjuvants in boosting humoral immunity, suggesting that adding adjuvants can significantly enhance vaccine efficacy.

Han et al. (2020) demonstrated that the IFNL3-adjuvanted DNA vaccine not only increased virus-specific T cell responses but also decreased regulatory T cells, suggesting enhanced antiviral and antitumor immunity. This dual action is particularly beneficial for chronic infections where immune modulation is critical. Firbas et al. (2006) found dose-dependent immune responses, essential for determining the optimal dose that maximizes immunogenicity while minimizing adverse effects, providing a basis for dose optimization in future trials. Jacobson et al. (2023) and Yutani et al. (2015) reported enhanced immune responses tailored to both viral and tumor antigens, offering insights into personalized vaccine strategies for high-risk populations. Personalization in vaccine development is crucial for addressing individual patient needs and optimizing therapeutic outcomes.

Safety

Safety is paramount in vaccine development, and all reviewed studies prioritized the evaluation of adverse effects, reporting generally favorable outcomes. Swadling et al. (2014) and Hartnell et al. (2019) reported favorable safety profiles, with only mild to moderate adverse events, indicating the tolerability of adenoviral vector-based vaccines, supporting the continued use of these vectors in vaccine development. Di Bisceglie et al. (2014) and Colombatto et al. (2014) highlighted that combination therapies with vaccines were well tolerated, with no significant increase in adverse effects compared to standard treatments alone, supporting the feasibility of integrating vaccines into existing treatment regimens.

Han et al. (2020) found that the IFNL3-adjuvanted DNA vaccine was well tolerated, with safety profiles comparable to other DNA vaccines, encouraging further development of DNA-based vaccines. Firbas et al. (2006) emphasized the importance of dose optimization, reporting that higher doses were associated with increased adverse events, underscoring the need for careful dose selection to balance efficacy and safety. Jacobson et al. (2023) and Yutani et al. (2015) reported good safety profiles, critical for vaccines targeting both viral and tumor antigens, with the ability to safely target multiple antigens being a significant advantage for therapeutic vaccines. Page et al. (2021), with its large

Phase III trial, provided robust data on safety, confirming that the vaccine regimen was well tolerated in a large, diverse population, which is particularly important for establishing the vaccine's safety profile across different demographic groups.

Efficacy Outcomes

Efficacy outcomes varied across the studies, reflecting different endpoints and population characteristics, but generally showing promising results. Swadling et al. (2014) demonstrated the ability of their vaccine strategy to sustain functional HCV-specific T cell memory, an essential component of long-term viral control, suggesting that the vaccine could provide lasting protection against HCV. Hartnell et al. (2019) showed that their vaccine strategy could prevent coinfection with HIV-1 and HCV, highlighting the potential for integrated vaccination programs in at-risk populations, with this dual prevention approach being highly beneficial in regions with high rates of both infections.

Di Bisceglie et al. (2014) reported significant reductions in viral load with the TG4040 vaccine, particularly when combined with peg-interferon and ribavirin, suggesting that vaccines can enhance the efficacy of existing antiviral treatments, offering a more comprehensive approach to HCV management. Colombatto et al. (2014) found that the E1E2-MF59 vaccine improved antibody responses in patients already receiving standard antiviral therapy, indicating potential benefits in boosting humoral immunity and enhancing overall treatment outcomes, with the use of adjuvants appearing to be a key factor in enhancing vaccine efficacy.

Han et al. (2020) demonstrated that the IFNL3-adjuvanted DNA vaccine not only increased virus-specific T cell responses but also reduced regulatory T cells, which can suppress immune responses, enhancing the vaccine's therapeutic potential in chronic HCV infection, potentially leading to better long-term outcomes. Firbas et al. (2006) established the optimal dose for their peptide vaccine, achieving a balance between immunogenicity and safety, providing critical data for designing future trials and ensuring effective vaccine deployment, setting a precedent for future dose optimization studies.

Jacobson et al. (2023) showed that their therapeutic DNA vaccine could prevent the development of hepatocellular carcinoma in patients with chronic HCV infection, a significant advance in cancer prevention strategies, highlighting the potential of vaccines not only in preventing viral infections but also in reducing cancer risk. Yutani et al. (2015) reported that personalized peptide vaccination tailored to individual antigen profiles could enhance tumor-specific immune responses, offering a promising approach for treating advanced hepatocellular carcinoma in HCV-positive patients, with personalization in vaccine strategies potentially improving patient outcomes.

Page et al. (2021) demonstrated that their vaccine regimen could prevent chronic HCV infection in a large, diverse population, providing strong evidence for the vaccine's potential to reduce the incidence of chronic HCV and associated complications, with this large-scale efficacy data being crucial for supporting the use of the vaccine in broader populations.

Challenges and Future Directions

Despite these promising results, several challenges remain in the development of an effective HCV vaccine. One significant hurdle is the high genetic variability of HCV, particularly in the E2 region, which complicates the design of broadly protective vaccines. The virus's ability to evade immune responses through rapid mutation and the existence of multiple genotypes and quasispecies within individuals necessitate vaccines that can elicit broad and potent immune responses (Smith et al., 2014).

Another challenge is the induction of durable and protective immune responses. While many vaccine candidates have shown strong initial immunogenicity, maintaining these responses over time is crucial for long-term protection. Strategies to enhance the durability of immune responses, such as optimizing prime-boost regimens and incorporating novel adjuvants, are essential areas of ongoing research (Duncan et al., 2020).

Moreover, the balance between safety and efficacy remains a critical consideration. While viral vector-based vaccines have shown strong immunogenicity, their safety profiles need continuous monitoring, especially when used in combination with other treatments. The development of vaccines with minimal adverse events while maintaining high efficacy is a priority (Custers et al., 2021).

The integration of therapeutic vaccines into existing treatment regimens presents both opportunities and challenges. Therapeutic vaccines, like TG4040, have shown potential in boosting the efficacy of DAAs and enhancing immune responses in chronically infected patients. However, managing the adverse events associated with these treatments and ensuring their compatibility with existing therapies are critical (Sandmann et al., 2019).

Future Directions

To address these challenges, future research should focus on several key areas:

Broadening the Scope of Immune Responses: Developing vaccines that target multiple viral antigens and induce both humoral and cellular immune responses can enhance the breadth and potency of the immune response. This approach may mitigate the impact of viral variability and improve vaccine efficacy across different HCV genotypes (Tarr et al., 2015).

Optimizing Vaccine Regimens: Refining prime-boost strategies and exploring new combinations of viral vectors and adjuvants can enhance the durability and magnitude of immune responses. Ongoing trials should investigate the optimal timing and dosing of vaccine administration to achieve sustained protection (Capone et al., 2020).

Addressing Safety Concerns: Ensuring the safety of HCV vaccines is paramount. Continuous monitoring and evaluation of adverse events in clinical trials, coupled with the development of vaccines with minimal reactogenicity, are essential. Innovative delivery systems and formulations that minimize adverse events while maintaining high immunogenicity should be explored (Pollard & Bijker, 2021).

Personalized Approaches: Personalized peptide vaccines tailored to individual HLA types have shown promise in enhancing immune responses and improving clinical outcomes. Expanding this approach to broader populations and integrating it with other therapeutic strategies could provide significant benefits (Yutani et al., 2015).

Combination Therapies: Integrating therapeutic vaccines with existing antiviral treatments, such as DAAs, can enhance overall treatment efficacy. Combination therapies that include immune modulators or checkpoint inhibitors may further boost immune responses and improve clinical outcomes in chronically infected patients (Sandmann et al., 2019).

Addressing Reinfection: Developing vaccines that provide long-term immunity and prevent reinfection is crucial, particularly for high-risk populations. Strategies to induce strong memory T-cell responses and neutralizing antibodies are essential to achieve durable protection (Midgard et al., 2016).

Global Accessibility: Ensuring that effective HCV vaccines are accessible to populations in resource-limited settings is critical for global health. Efforts to reduce vaccine costs, streamline manufacturing processes, and enhance distribution networks are necessary to achieve widespread vaccination coverage (Stone et al., 2016).

Conclusion

The reviewed studies provide a comprehensive overview of HCV vaccine development, highlighting the crucial role of targeted proteins, particularly non-structural and core proteins, in inducing robust immune responses. Utilizing various vaccine platforms—viral vector-based (Chimpanzee adenovirus and Modified Vaccinia Ankara vectors), peptide-based, and recombinant protein vaccines—these studies demonstrate significant immunogenicity, safety, and efficacy. Viral vector-based vaccines showed strong T-cell responses and high polyfunctional CD8+ and CD4+ T-cell levels, while peptide-based vaccines, tailored to individual patients, enhanced immune responses and survival in HCV-positive advanced HCC patients. Recombinant protein vaccines effectively elicited both cellular and humoral immune responses, preventing chronic HCV infection. The immunogenicity results underscore the importance of both cellular and humoral immunity, with favorable safety profiles and promising efficacy in preventing chronic infection, reducing viral load, and enhancing immune responses in combination with standard therapies. Adjuvants and combination strategies further enhance these outcomes, suggesting that integrated approaches may be most effective. These studies lay a strong foundation for future HCV vaccine development, emphasizing the need for ongoing research to address challenges such as genetic variability and optimizing formulations for diverse populations, ultimately promising to reduce the global burden of HCV and improve patient outcomes.

Bibliography

Bailey, J. R., Barnes, E., & Cox, A. L. (2019). Approaches, progress, and challenges to hepatitis C vaccine development. *Gastroenterology*, *156*(2), 418-430. https://www.gastrojournal.org/article/S0016-5085(18)35035-2/pdf

Barnes, E., Folgori, A., Capone, S., Swadling, L., Aston, S., Kurioka, A., Meyer, J., Huddart, R., Smith, K., & Townsend, R. (2012). Novel adenovirus-based vaccines induce broad and sustained T cell responses to HCV in man. *Science translational medicine*, *4*(115), 115ra111-115ra111.

Capone, S., Brown, A., Hartnell, F., Sorbo, M. D., Traboni, C., Vassilev, V., Colloca, S., Nicosia, A., Cortese, R., & Folgori, A. (2020). Optimising T cell (re) boosting strategies for adenoviral and modified vaccinia Ankara vaccine regimens in humans. *npj Vaccines*, *5*(1), 94.

Chen, S. L., & Morgan, T. R. (2006). The natural history of hepatitis C virus (HCV) infection. *International journal of medical sciences*, *3*(2), 47.

Colombatto, P., Brunetto, M. R., Maina, A., Romagnoli, V., Almasio, P., Rumi, M., Ascione, A., Pinzello, G., Mondelli, M., & Muratori, L. (2014). HCV E1E 2-MF 59 vaccine in chronic hepatitis C patients treated with PEG-IFN α2a and R ibavirin: a randomized controlled trial. *Journal of Viral Hepatitis*, *21*(7), 458-465.

Custers, J., Kim, D., Leyssen, M., Gurwith, M., Tomaka, F., Robertson, J., Heijnen, E., Condit, R., Shukarev, G., & Heerwegh, D. (2021). Vaccines based on replication incompetent Ad26 viral vectors: Standardized template with key considerations for a risk/benefit assessment. *Vaccine*, *39*(22), 3081-3101.

De Jong, Y. P., Dorner, M., Mommersteeg, M. C., Xiao, J. W., Balazs, A. B., Robbins, J. B., Winer, B. Y., Gerges, S., Vega, K., & Labitt, R. N. (2014). Broadly neutralizing antibodies abrogate established hepatitis C virus infection. *Science translational medicine*, *6*(254), 254ra129-254ra129.

Di Bisceglie, A. M., Janczweska–Kazek, E., Habersetzer, F., Mazur, W., Stanciu, C., Carreno, V., Tanasescu, C., Flisiak, R., Romero–Gomez, M., & Fich, A. (2014). Efficacy of immunotherapy with TG4040, peg-interferon, and ribavirin in a Phase 2 study of patients with chronic HCV infection. *Gastroenterology*, *147*(1), 119-131. e113.

Drummer, H. E. (2014). Challenges to the development of vaccines to hepatitis C virus that elicit neutralizing antibodies. *Frontiers in microbiology*, *5*, 329.

Duncan, J. D., Urbanowicz, R. A., Tarr, A. W., & Ball, J. K. (2020). Hepatitis C virus vaccine: challenges and prospects. *Vaccines*, *8*(1), 90.

Firbas, C., Jilma, B., Tauber, E., Buerger, V., Jelovcan, S., Lingnau, K., Buschle, M., Frisch, J., & Klade, C. S. (2006). Immunogenicity and safety of a novel therapeutic hepatitis C virus (HCV) peptide vaccine: a randomized, placebo controlled trial for dose optimization in 128 healthy subjects. *Vaccine*, *24*(20), 4343-4353.

Han, J. W., Sung, P. S., Hong, S.-H., Lee, H., Koh, J. Y., Lee, H., White, S., Maslow, J. N., Weiner, D. B., & Park, S.-H. (2020). IFNL3-adjuvanted HCV DNA vaccine reduces regulatory T cell frequency and increases virus-specific T cell responses. *Journal of Hepatology*, *73*(1), 72-83.

Hartnell, F., Brown, A., Capone, S., Kopycinski, J., Bliss, C., Makvandi-Nejad, S., Swadling, L., Ghaffari, E., Cicconi, P., & Del Sorbo, M. (2019). A novel vaccine strategy employing serologically different chimpanzee adenoviral vectors for the prevention of HIV-1 and HCV coinfection. *Frontiers in immunology*, *9*, 3175.

Jacobson, J. M., Zahrieh, D., Strand, C. A., Cruz-Correa, M., Pungpapong, S., Roberts, L. R., Mandrekar, S. J., Rodriguez, L. M., Boyer, J., & Marrero, I. (2023). Phase I Trial of a Therapeutic DNA Vaccine for Preventing Hepatocellular Carcinoma from Chronic Hepatitis C Virus (HCV) Infection. *Cancer Prevention Research*, *16*(3), 163-173.

Midgard, H., Weir, A., Palmateer, N., Re III, V. L., Pineda, J. A., Macías, J., & Dalgard, O. (2016). HCV epidemiology in high-risk groups and the risk of reinfection. *Journal of Hepatology*, *65*(1), S33-S45.

Page, K., Melia, M. T., Veenhuis, R. T., Winter, M., Rousseau, K. E., Massaccesi, G., Osburn, W. O., Forman, M., Thomas, E., & Thornton, K. (2021). Randomized trial of a vaccine regimen to prevent chronic HCV infection. *New England Journal of Medicine*, *384*(6), 541-549.

Pollard, A. J., & Bijker, E. M. (2021). A guide to vaccinology: from basic principles to new developments. *Nature Reviews Immunology*, *21*(2), 83-100.

Rehermann, B., & Thimme, R. (2019). Insights from antiviral therapy into immune responses to hepatitis B and C virus infection. *Gastroenterology*, *156*(2), 369-383.

Sandmann, L., Schulte, B., Manns, M. P., & Maasoumy, B. (2019). Treatment of chronic hepatitis C: efficacy, side effects and complications. *Visceral medicine*, *35*(3), 161-170.

Simmonds, P., Bukh, J., Combet, C., Deléage, G., Enomoto, N., Feinstone, S., Halfon, P., Inchauspé, G., Kuiken, C., & Maertens, G. (2005). Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. *Hepatology*, *42*(4), 962-973.

Smith, D. B., Bukh, J., Kuiken, C., Muerhoff, A. S., Rice, C. M., Stapleton, J. T., & Simmonds, P. (2014). Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and genotype assignment web resource. *Hepatology*, *59*(1), 318-327.

Stone, J., Martin, N. K., Hickman, M., Hellard, M., Scott, N., McBryde, E., Drummer, H., & Vickerman, P. (2016). The potential impact of a hepatitis C vaccine for people who inject drugs: is a vaccine needed in the age of direct-acting antivirals? *PLoS One*, *11*(5), e0156213.

Swadling, L., Capone, S., Antrobus, R. D., Brown, A., Richardson, R., Newell, E. W., Halliday, J., Kelly, C., Bowen, D., & Fergusson, J. (2014). A human vaccine strategy based on chimpanzee adenoviral and MVA vectors that primes, boosts, and sustains functional HCV-specific T cell memory. *Science translational medicine*, *6*(261), 261ra153-261ra153.

Tarr, A. W., Khera, T., Hueging, K., Sheldon, J., Steinmann, E., Pietschmann, T., & Brown, R. J. (2015). Genetic diversity underlying the envelope glycoproteins of hepatitis C virus: structural and functional consequences and the implications for vaccine design. *Viruses*, *7*(7), 3995-4046.

Walker, C. M. (2010). Adaptive immunity to the hepatitis C virus. *Advances in virus research*, *78*, 43-86.

Walker, C. M., & Grakoui, A. (2015). Hepatitis C virus: why do we need a vaccine to prevent a curable persistent infection? *Current opinion in immunology*, *35*, 137-143.

WHO. (2017). *Global hepatitis report 2017*. World Health Organization.

Yutani, S., Ueshima, K., Abe, K., Ishiguro, A., Eguchi, J., Matsueda, S., Komatsu, N., Shichijo, S., Yamada, A., & Itoh, K. (2015). Phase II study of personalized peptide vaccination with both a hepatitis C virus-derived peptide and peptides from tumor-associated antigens for the treatment of HCV-positive advanced hepatocellular carcinoma patients. *Journal of Immunology Research*, *2015*(1), 473909.